**Fiscal Year 2016 (FY16) Prostate Cancer Research Program (PCRP)
Reference Table of Award Mechanisms and Submission Requirements**

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| **Impact Award**<br><i>(modified!)</i> | Independent investigators at or above the level of Assistant Professor (or equivalent) | • Preproposal is required; application submission is by invitation only.  
• Supports high-impact, potentially high-risk, studies (including clinical trials) that address a central question or problem in prostate cancer. As such, the primary emphasis of this mechanism is on impact.  
• Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.  
• Proposed projects may include basic, translational, or clinical research, including clinical trials.  
• Preliminary data to support feasibility are required.  
• Partnering PI option:  
  o Provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.  
  o PIs are expected to demonstrate within the application the synergistic components that will significantly advance the project such that the research outcomes could not otherwise be accomplished through independent efforts of a single PI.  
  o Allows for individual awards to multiple sites (maximum of three sites in total), provided the combined direct costs for all sites does not exceed the $2M maximum. | Individual PIs:  
• Maximum funding of $750,000 (K) for direct costs (plus indirect costs)  
• Maximum period of performance is 3 years  
Partnering PI Option:  
• Maximum funding of $2M for direct costs (plus indirect costs)  
• Maximum period of performance is 3 years | Pre-application (Preproposal):  
June 9, 2016  
5:00 p.m. Eastern Time  
Application:  
August 25, 2016  
11:59 p.m. Eastern Time |

Go to:  
- Program Announcement  
- General Application Instructions  
Grants.gov Funding Opportunity Number: W81XWH-16-PCRP-IA
### Award Mechanism

**Health Disparity Research Award**

*Go to:*
- Program Announcement
- General Application Instructions
- Grants.gov Funding Opportunity Number: W81XWH-16-PCRP-HDRA

### Eligibility

**Established Investigators:**
- Independent investigators at or above the level of Assistant Professor (or equivalent); or
- New Investigators:
  - Investigator that meet the following criteria at the application submission deadline date:
    - Have the freedom to pursue individual aims without formal mentorship
    - Have not previously received a PCRP Health Disparity Research Award
    - If not in an independent faculty position (or equivalent), have completed at least 3 years of postdoctoral training or fellowship; or
    - If in an independent faculty position (or equivalent), are within 5 years of having begun work as an independent investigator

### Key Mechanism Elements

**New Investigators** supports applicants early in their faculty appointments or in the process of developing independent research careers.

**Qualified Collaborator Option** supports a higher level of funding for PIs who include a collaborator that significantly contributes (10% level of effort or greater and provides both intellectual input and research resources) to the research project such that it could not otherwise be accomplished.

**Nested Health Disparity Traineeship Option** supports predoctoral or postdoctoral training, nested within the overall proposed project, for individuals committed to pursuing careers as independent investigators in prostate cancer health disparity research.

### Funding

- **Maximum funding of $450K** for direct costs (plus indirect costs)
- **If applying for the Qualified Collaborator Option, maximum funding of $600K** for direct costs (plus indirect costs)
- **Maximum period of performance is 3 years**
- Additional funds can be requested if including the Nested HD Traineeship Option
  - Predoctoral PIs: maximum additional funds cannot exceed $92,500
  - Postdoctoral PIs: maximum additional funds cannot exceed $15,000

### Submission Deadline

- **Pre-application (Preproposal):**
  - June 9, 2016 5:00 p.m. Eastern Time
- **Application:**
  - August 25, 2016 11:59 p.m. Eastern Time
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Consortium Research Site Award</td>
<td>Independent investigators at or above the level of Assistant Professor (or equivalent)</td>
<td>• Supports research to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) prostate cancer clinical trials.&lt;br&gt;• Trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of prostate cancer, especially as pertaining to the FY16 PCRP overarching challenges.&lt;br&gt;• Principal goal of the Clinical Consortium Research Site Award is to combine the efforts of leading investigators to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease the impact of prostate cancer.</td>
<td>• Maximum funding of $800K for direct costs (plus indirect costs).&lt;br&gt;  o A total of $200K in direct costs (plus indirect costs) will be allocated from the FY16 budget to fund the first year of performance for each Site.&lt;br&gt;  o Options will be included for continued performance in subsequent years with $200K direct costs (plus indirect costs) expected from each of the FY17–FY19 budgets to fund the option years.&lt;br&gt;• Maximum period of performance is 4 years.&lt;br&gt;  o The initial performance period of the award and each option period will be for 12 months.</td>
<td>Pre-application (Letter of Intent): September 15, 2016 5:00 p.m. Eastern Time &lt;br&gt;Application: October 6, 2016 11:59 p.m. Eastern Time</td>
</tr>
</tbody>
</table>

Grants.gov Funding Opportunity Number: W81XWH-16-PCRP-CCRSA
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Idea Development Award (modified!)                  | *Established Investigators:* Independent investigators at or above the level of Assistant Professor (or equivalent); or *New Investigators:* Investigators that meet the following criteria at the application submission deadline date:  
  - Have the freedom to pursue individual aims without formal mentorship  
  - Have not previously received a PCRP Idea Development Award  
  - If not in an independent faculty position (or equivalent), have completed at least 3 years of postdoctoral training or fellowship  
  - If in an independent faculty position (or equivalent), are within 5 years of having begun work as an independent investigator | *Preproposal is required; application submission is by invitation only.*  
  *Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research, and have the potential to make an important contribution to eliminating death from prostate cancer and enhancing the well-being of men with prostate cancer.*  
  *Preliminary data are encouraged but not required.*  
  *Innovation, Impact, and Synergy (for Partnering PI applicants only) are the most important review criteria.*  
  *Clinical trials are not allowed.*  
  *New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.*  
  *Partnering PI Option:*  
    o Provides a higher level of funding to support synergistic partnerships between two or three independent *Established Investigators* collaborating on a single application.  
    o PIs are expected to demonstrate within the application the synergistic components that will significantly advance the project such that the research outcomes could not otherwise be accomplished through independent efforts of a single PI.  
    o Allows for individual awards to multiple sites (maximum of three sites in total), provided the combined direct costs for all sites does not exceed the $750K maximum. | *Established PIs:*  
  - Maximum funding of $600K for direct costs (plus indirect costs)  
  - Maximum period of performance is 3 years  
*New Investigator Option:*  
  - Maximum funding of $275K for direct costs (plus indirect costs)  
  - Maximum period of performance is 3 years  
*Partnering PI Option:*  
  - Maximum funding of $1M for direct costs (plus indirect costs)  
  - Maximum period of performance is 3 years | *Pre-application (Preproposal):*  
  June 23, 2016  
  5:00 p.m. Eastern Time  
*Application:*  
  October 6, 2016  
  11:59 p.m. Eastern Time |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician Research Award</td>
<td>At the time of application submission, the PI (who is the trainee) must be either:</td>
<td>• Supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research</td>
<td>• Maximum funding of $130K per year for direct costs (plus indirect costs)</td>
<td>Pre-application (Letter of Intent): July 7, 2016 5:00 p.m. Eastern Time</td>
</tr>
<tr>
<td></td>
<td>• In the last year of an accredited medical residency or medical fellowship program; or</td>
<td>• PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.</td>
<td>• Maximum period of performance is 4 years</td>
<td>Confidential Letters of Recommendation: July 26, 2016 5:00 p.m. Eastern Time</td>
</tr>
<tr>
<td></td>
<td>• Within 3 years of having initiated an appointment as Instructor, Assistant Professor, or equivalent</td>
<td>• PIs must have a designated mentor with an established research program in prostate cancer.</td>
<td></td>
<td>Application: July 21, 2016 11:59 p.m. Eastern Time</td>
</tr>
<tr>
<td>Go to:</td>
<td></td>
<td>• Institutions must provide at least 40% protection of PI’s time for research.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grants.gov Funding Opportunity Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W81XWH-16-PCRP-PRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award Mechanism</td>
<td>Eligibility</td>
<td>Key Mechanism Elements</td>
<td>Funding</td>
<td>Submission Deadline</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Early Investigator Research Award</td>
<td>By March 31, 2017,</td>
<td>• Supports prostate cancer-focused research opportunities for individuals in the early stages of their careers, PIs must have a designated mentor who is an experienced prostate cancer researcher.</td>
<td>Maximum period of performance is 2 years</td>
<td>Pre-application (Letter of Intent):</td>
</tr>
<tr>
<td></td>
<td>The Predoctoral PI must:</td>
<td></td>
<td>Predoctoral PIs:</td>
<td>July 7, 2016 5:00 p.m. Eastern Time</td>
</tr>
<tr>
<td></td>
<td>• Be enrolled full-time in an accredited doctoral program; and</td>
<td></td>
<td>• Maximum of $60K for direct costs (plus indirect costs)</td>
<td>Confidential Letters of Recommendation:</td>
</tr>
<tr>
<td></td>
<td>• Must have successfully completed comprehensive examinations or otherwise met predissertation requirements</td>
<td></td>
<td>Postdoctoral PIs:</td>
<td>July 26, 2016 5:00 p.m. Eastern Time</td>
</tr>
<tr>
<td></td>
<td>The Postdoctoral PI must:</td>
<td></td>
<td>• Maximum of $125K for direct costs (plus indirect costs)</td>
<td>Application:</td>
</tr>
<tr>
<td></td>
<td>• Have successfully defended a doctoral thesis or possess an M.D. degree, and</td>
<td></td>
<td></td>
<td>July 21, 2016 11:59 p.m. Eastern Time</td>
</tr>
</tbody>
</table>